Nippon Shinyaku has been granted a patent for new crystals of (S)-N2-[1-(4-fluorophenyl)ethyl]-4-(1-methyl-1H-pyrazol-4-yl)-N6-(pyrazin-2-yl)pyridine-2,6-diamine maleate. The patent claims a Form-I crystal of the compound, which exhibits specific diffraction peaks in its X-ray powder diffraction spectrum. GlobalData’s report on Nippon Shinyaku gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Nippon Shinyaku, cancer treatment biomarkers was a key innovation area identified from patents. Nippon Shinyaku's grant share as of June 2023 was 1%. Grant share is based on the ratio of number of grants to total number of patents.
Patent granted for form-i crystal of compound a
A recently granted patent (Publication Number: US11680055B2) discloses a new crystal form of a compound called (S)-N2-[(1-(4-fluorophenyl)ethyl]-4-(1-methyl-1H-pyrazol-4-yl)-N6-(pyrazin-2-yl)pyridine-2,6-diamine maleate. This crystal, referred to as Form-I, exhibits specific diffraction peaks in its X-ray powder diffraction spectrum at certain angles of diffraction. The X-ray powder diffraction spectrum is obtained using Cu Ka radiation. The diffraction peaks occur at 6.9 degrees, 9.4 degrees, 12.5 degrees, 15.1 degrees, 16.4 degrees, 18.3 degrees, 19.0 degrees, 24.9 degrees, 25.4 degrees, 27.3 degrees, and 27.7 degrees.
Additionally, the patent claims that Form-I crystal of (S)-N2-[1-(4-fluorophenyl)ethyl]-4-(1-methyl -1H-pyrazol-4-yl)-N6-(pyrazin-2-yl)pyridine-2,6-diamine maleate exhibits an endothermic peak at 203±3° C. in differential scanning calorimetry. This indicates a specific thermal behavior of the crystal when subjected to heat.
The patent also covers pharmaceutical compositions containing the Form-I crystal as an active ingredient along with a pharmaceutically acceptable carrier. This suggests that the crystal may have potential applications in the development of new drugs or therapies. The compositions can be formulated to deliver the active ingredient in a suitable manner for therapeutic use.
In summary, the granted patent describes a newly discovered crystal form of (S)-N2-[(1-(4-fluorophenyl)ethyl]-4-(1-methyl-1H-pyrazol-4-yl)-N6-(pyrazin-2-yl)pyridine-2,6-diamine maleate, referred to as Form-I. This crystal exhibits specific diffraction peaks in its X-ray powder diffraction spectrum and shows an endothermic peak at 203±3° C. in differential scanning calorimetry. The patent also covers pharmaceutical compositions containing the Form-I crystal as an active ingredient, opening up potential applications in the field of medicine.
To know more about GlobalData’s detailed insights on Nippon Shinyaku, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
